You are here: Industry Insights > RHB-107

News List

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients prnewswire
November 16, 2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the last patient has been enrolled in Part A of the Phase 2/3 study with novel...
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 prnasia
May 27, 2021
RedHill Biopharma Ltd. announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib[1] and RHB-107 (upamostat)[2] as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus.
ObvioHealth and RedHill to begin remote Covid-19 therapy trial pharmaceutical-technology
March 04, 2021
ObvioHealth is set to initiate a Phase II/III study of RedHill Biopharma’s RHB-107 (upamostat) in the US for Covid-19 treatment.
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 prnasia
February 18, 2021
RedHill Biopharma Ltd. announced that the first patient was dosed in its U.S. Phase 2/3 study of orally-administered RHB-107 (upamostat)[1], an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
RedHill Biopharma's Second COVID-19 Candidate Cleared by FDA for Phase 2/3 Study americanpharmaceuticalreview
November 26, 2020
RedHill Biopharma announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered RHB-107 (upamostat) in patients with symptomatic COVID-19 ...
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease prnasia
November 20, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered ...
RedHill Biopharma to initiate Phase II/III trial of Covid-19 candidate pharmaceutical-technology
November 19, 2020
RedHill Biopharma is set to start the Phase II/III study evaluating orally administered RHB-107 (upamostat) in patients with symptomatic Covid-19 who do not require hospitalisation.
RedHill Receives Patent Allowance Covering Opaganib, RHB-107 Combination americanpharmaceuticalreview
November 13, 2020
RedHill Biopharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application related to the use of two of RedHill’s proprietary investigational compounds, opaganib (Yeliva®, ABC294640) and ..
RedHill Biopharma partners with NIAID for potential Covid-19 drug pharmaceutical-technology
April 22, 2020
Israel-based RedHill Biopharma has partnered with the US National Institute of Allergy and Infectious Diseases (NIAID) to study its RHB-107 (upamostat, WX-671) drug candidate in non-clinical tests for the treatment of Covid-19.